Genetic variants are risk factors for coronary disease, but their role in recurrent events and in response to treatment is less clear. We genotyped genetic variants implicated in primary coronary disease in 924 Caucasians with acute coronary syndromes participating in the OPUS-TIMI16 trial of the GPIIb/IIIa antagonist orbofiban. These were the platelet glycoprotein (GP) receptors GPIIIa, GPIa, GPIb␣; platelet ligands ␤-fibrinogen and von Willebrand Factor (vWF); interleukins (IL) IL-1RN, and IL-6; adhesion proteins E-selectin and Pselectin; and metalloproteinase MMP-9. Cox modelling of all genetic variants demonstrated no significant impact on the composite endpoint (P ϭ 0.88), which included myocardial infarction (MI), death, recurrent ischemia, urgent revascularisation and stroke, but a significant impact on recurrent myocardial infarction alone ( 2 ϭ 20.4, 10 df, P = 0.04). There was a significant interaction of the polymorphisms with orbofiban treatment influencing bleeding outcomes (P ϭ 0.004). Thus, genetic polymorphisms may be associated with subsequent myocardial infarction, and may also be associated with treatment-associated bleeding among coronary patients.
INTRODUCTION
Genetic factors have a clear impact on the development of coronary artery disease, as established by studies of twin disease concordance and by case-control or prospective studies of genetic polymorphism. 1, 2 Given the complexity and overlap of atherosclerotic and thrombotic disease processes, it is not clear whether such factors continue to be associated with the recurrence risk of coronary events in patients with a history of unstable coronary syndromes. Currently, there is little or no clinical data regarding this important question.
To address this issue, we analysed genetic variation in a population with Acute Coronary Syndromes, presenting with either unstable angina or myocardial infarction. These patients participated in the OPUS TIMI-16 clinical trial of oral glycoprotein GPIIb/IIIa antagonists, 3 and were followed prospectively to determine the incidence of recurrent events and of bleeding complications. Our initial analyses of the PLA2 polymorphism 4 and the GPIb␣ T-5C variant 5 in this population suggested that these individual factors appeared to modulate disease risk. However, no single common genetic variant confers a very large risk of coronary ischemia, so that a particular association is unlikely to be consistently found without very large sample sizes. 6 Secondly, underlying genetic risks conferred by a particular polymorphism are likely to vary from study to study according to differences in inclusion criteria, treatment, and diagnostic definition of events. Therefore, individual estimates of risk of recurrent disease conferred by particular genetic factors are unlikely to be easily reproduced. For this reason, we concentrated on the broader question: over a number of genes, is there a significant difference in the overall distribution of risk alleles among patients who experience a recurrent event during follow-up, compared to those who do not? This provides a single test of whether genetic factors in general continue to be of relevance in determining the prognosis of patients with acute coronary syndromes.
Ten genetic variants with a probable role in primary cardiovascular disease were genotyped to determine what role they have to play in recurrent disease. The variants chosen reflected an interest in the possible roles of thrombosis and inflammation in recurrent disease. The genes examined play roles in various processes associated with thrombus formation. Metalloproteinases can contribute to the rupture of an atherosclerotic plaque; selectins play roles in platelet and endothelial adhesion; platelet ligands vWF and fibrinogen initiate adhesion and activation of platelets, mediated by their receptors GPIb and GPIIb/IIIa; and pro-inflammatory proteins contribute to the pro-thrombotic milieu. The study was confined to polymorphisms with a previously identified influence on primary disease, in order to maximize the power to detect an association of genetics with recurrent disease. The endpoints studied were: (1) the main study composite endpoint; (2) bleeding events; and (3) MI alone, which is the subset of composite endpoints with the clearest thrombotic component. Their impact was found to be greatest on MI outcome, while the main influence of the genotypes on response to treatment was on the bleeding outcome in patients.
MATERIALS AND METHODS

Study Population
The analysis was a sub-study of OPUS-TIMI 16, a phase III multicenter, double-blind and placebo-controlled trial evaluating the efficacy and safety of orbofiban, a GPIIb/IIIa antagonist, in patients with unstable coronary syndromes. 3 Between October 1997 and November 1998, 10 288 patients were recruited from 888 hospitals in 29 countries. Of these, 1023 provided separate written, informed consent for genetic analysis and 1014 provided samples from which DNA was extracted. Patient recruitment for the genetic study was limited to those sites for which ethical approval had been obtained prior to the early termination of the main study. 7 Patients who withdrew from the study prior to genetics sampling were not required to return to the clinic, and were therefore not sampled.
Consent and bloods were obtained at the randomisation visit or at a subsequent visit, for analysis of genetic variation in relation to cardiovascular disease and therapy. Analysis was performed on a database free of patient identifiers to protect anonymity.
The protocol for the main study has been outlined in detail elsewhere. 3 Briefly, the inclusion criteria were ischemic discomfort at rest for at least 5 min within the previous 72 h with one of the following: (1) new or presumably new electrocardiographic changes (ST segment deviation Ն 0.5 mm, T-wave inversion Ն 3 mm in at least three contiguous www.nature.com/tpj leads or left bundle branch block); (2) positive serum markers; (3) history of myocardial infarction (MI), angioplasty, bypass surgery or coronary stenosis Ն 50%; (4) age Ն 65 years and a history of angina or positive stress test; (5) prior transient ischemic attack or non-hemorrhagic stroke; (6) peripheral vascular disease; or (7) diabetes mellitus. All patients received aspirin 150-162 mg daily and were randomized to one of three groups: (1) orbofiban 50 mg twice daily for 30 days, followed by 30 mg twice daily; (2) orbofiban 50 mg twice daily for 30 days, followed by 50 mg twice daily; (3) placebo. The actual treatment period ranged from 1 month to a maximum of approximately 15 months.
The main study's primary end-point was a composite of: (1) death; (2) MI; (3) recurrent ischemia at rest leading to rehospitalization; (4) urgent revascularization; and (5) stroke. A Clinical Events Committee adjudicated all endpoints. Additional analyses were performed for myocardial infarction and for all recorded coronary ischemic events. Bleeding was defined as any severe, major or minor bleeding event.
Rationale for Choice of Variants Genotyped
The platelet glycoprotein receptor GPIIb/IIIa PLA2 variant is associated with cardiovascular events in some studies. Perhaps the most convincing finding has been a high risk conferred in a study of 200 early onset cases under 45 years of age, where those PLA2-carrying subjects who smoked were at high risk; 8 but larger studies of older onset patients have not identified a convincing association. 2 The ␤-fibrinogen promoter variant Ϫ455A is consistently associated with higher protein levels of fibrinogen, but shows inconsistent and contradictory association with cardiovascular disease in different studies. 2 The platelet glycoprotein receptor GPIb␣ Kozak variant Ϫ5C is associated with raised receptor density 9 and with cardiovascular events in one study 9 but not in another. 10 The vWF promoter variant Ϫ1051A polymorphism shows differential binding to nuclear extracts, implying a possible involvement in transcription factor binding; 11 vWF levels are a strong risk factor for unstable coronary disease 12 and an initial report implicated these polymorphisms in coronary disease. 13 The platelet glycoprotein collagen receptor GPIa (integrin alpha-2) silent variant 807T 14 is associated with higher collagen receptor density and with increased cardiovascular event rates, 15 although this association is not consistent.
2 This variant has recently been shown to be in disequilibrium with a promoter variant, 16 most likely explaining its association with altered receptor densities. The 807T variant appears also to be possibly associated with lower risk of bleeding 17 in patients with von Willebrand's disease.
Interleukin-1 receptor antagonist Variable Number of Tandem Repeats IL1RN*2 variant has been associated with coronary artery disease in a study of over 500 subjects which found no role for TNF alpha , IL-1A and IL1-B variants. 18 A recent study has indicated that it is in linkage disquilibrium with the IL1-B promoter variants (Ϫ31 and Ϫ511) but not with the IL-1B coding sequence variant (IL-1B+3954), and that the IL1-RN*2 allele is associated with enhanced IL-1B production in vitro. 19 Interleukin-6 promoter Ϫ174G variant is associated with raised levels of IL-6 and with juvenile arthritis. 20 It has recently been shown to be associated with atherosclerosis. 21 E-selectin Ser128Arg variant may increase MI 22 and angiographically detected cardiovascular disease.
23
P-selectin 715Pro may protect against cardiovascular events, 24 a finding that has been confirmed when the population was enlarged. 25 The Metalloproteinase 9 (gelatinase B) promoter variant Ϫ1562T is associated with raised levels of MMP-9 and implicated in coronary atherosclerosis but not with coronary events in a case-control comparison. 26 This more highly expressed variant has the potential to increase coronary events by causing plaque rupture leading to major thrombi, and to decrease events by limiting the progression of restenosis requiring revascularisation.
Genotyping
The 1014 patients (924 Caucasian) were genotyped for 11 variants ( Table 1 ). The number of assays which failed due to poor quality DNA was low, with between 0 and 3 samples for which the genotype could not be inferred, depending on the genotyping assay. The majority of genotypes were determined by allele-specific restriction digestion followed by sizing on agarose gels; in each assay a second site was always cut to ensure the presence of a positive control for the correct action of the restriction enzyme. Primers chosen for genomic DNA amplification were obtained from assays previously described for IL1RN 27 and MMP9; 26 other primers were chosen to flank restriction sites appropriately ( Table 1) . The restriction assay for GPIb-5C has been previously described. 28 Similar methods were employed for ␤-fibrinogen, IL-6, MMP-9, E-selectin, P-selectin, vWF (see Table 1 ). The GPIIIa PLA2 genotype was determined by heteroduplex analysis. 29 Agarose gel sizing was used to determine the genotype of Variable number tandem repeats (VNTR) IL1RN polymorphism (see Table 1 for details of PCR primers and predicted product sizes).
GPIa was genotyped on HPLC, following the approach of Hoogendoom et al. 30 PCR for the 101 bp used forward primer TGATTGTAGCAACATCCCAGAC and reverse primer TTGGCCTATTAGCACCAAAAC. Shrimp alkaline phosphatase (SAP) (0.5 units) and Exonuclease 1 (1.5 units) both from Amersham (Little Chalfont, Bucks, UK) were added to the PCR product and incubated at 37°C for 30 min, followed by incubation at 80°C for 15 min. Primer extension reactions were carried out using the primer CTTACCTTGCAT-ATTGAATTGCTCC, dATPs, dTTPs, ddGTPs and 1 unit Thermo Sequenase (Amersham). Detection was carried out by HPLC (WAVE Transgenomic, Santa Clara, CA, USA) at 70°C.
Statistical Analysis
The endpoints studied were: (1) the main study composite endpoint; (2) bleeding events; and (3) MI alone, which is the subset of composite endpoints with the clearest thrombotic component. While stroke is also a very interesting endpoint
The Pharmacogenomics Journal with a previously identified genetic component, the number of strokes was too few to consider in this study. The number of deaths was also too few to be considered as a separate endpoint. Minor, severe and major bleeds were combined to define a dichotomous variable.
Association studies of genotypic variants with clinical phenotypes must carefully address the issue of false positive or false negative results. False positive or false negative results may arise through the confounding of genotype frequencies at a particular locus with other genetic or ethnic components of disease risk. This confounding is likely to be minimised if the analysis is restricted to a single race. Since Caucasians comprised the large majority of study participants, and the level of intra-population variability within Caucasians is low, 31 our main analysis was restricted to 924 Caucasians, thus controlling for the major component of genetic substructure 32 in the study population. Caucasians were defined in the OPUS study as persons of white race, as opposed to the alternative definitions of black, asian, hispanic/latin american, or other.
Survival analysis considered the association between genotype and the time to first event for each of myocardial infarction, composite endpoint, and the first severe, major, or minor bleeding. Baseline covariates which correlate strongly with outcome and with each other can confound apparent genetic components of treatment related response. In particular, differences due to geographic and ethnic origin can create spurious genetic associations, since genotypes and mortality vary between races, and to a lesser extent among countries. Carrier status was defined as 0 for the genotype homozygous for the other allele, and defined as 1 for both heterozygote carriers of the allele, and for those patients homozygous for the allele. Results are based on a Cox proportional hazards model, which allowed the adjustment for possible confounding effects of other prognostic risk factors. Tests of interaction between genotype and treatment effect were performed by fitting additional terms within the survival model, which also included genotype and treatment. The statistical significance of the interaction term was assessed using the likelihood ratio test. Individual assessments of the roles of each genetic factor in turn are possible, but much larger samples are required 3 in order to narrow confidence intervals and to establish their role in the light of correction for multiple testing. Instead, a single statistical test was applied. For each gene, carrier status for a single allelic variant was analysed (the 10 alleles are indicated in Figure 1 ). Cox proportional hazards regression of the influence of all 10 variants on disease outcome was performed. This was adjusted for age, sex, country and treatment, and considered the additive effects of the 10 genetic variants. Thus, each of the 10 variants was included as a separate variable in a Cox proportional hazards analysis together with variables that were adjusted for. Significance was assessed using the likelihood ratio test. Since 10 polymorphisms were fitted, the likelihood ratio test has ten degrees of freedom. This test is essentially to answer the question: do components of a patient's genetic background, which are thought to influence likelihood of a primary event, influence the likelihood that a patient with coronary disease will have recurrent events? Where 10 polymorphisms were considered along with each of their interactions with treatment, the test for interaction had 10 degrees of freedom (comparing a model with 10 carrier status terms and one treatment term, with a model which had in addition the 10 terms for each interaction between carrier status and treatment).
Outcomes are likely to be influenced by gene-gene interactions. However, with 45 possible pairwise interactions there is insufficient statistical power, so we limited our investigation to one gene-gene interaction. Much of the evidence concerning the role of inflammation (and infection) in thrombosis 4 is obscured by concerns whether the inflammation is the cause or consequence of the coronary disease process. We tested whether pro-inflammatory variants interact with platelet pro-thrombotic factors in the population. We defined a pro-thrombotic genotype as carrying one of GPIa T, GPIb Ϫ5C, GPIIb/IIIa PLA2, and a proinflammatory genotype as carrying both IL1RN*2 and IL-6 G.
It is conventional in cardiovascular research to adjust for the major risk factors in statistical analysis, firstly to deterwww.nature.com/tpj mine whether a fitted parameter simply confers its risk mediated through those known factors or operates through an independent pathway, or secondly to reduce variability resulting from those known factors. We have chosen not to adjust for these factors in our primary analysis, since genetic effects are not a by-product of the major risk factors, and we wish to avoid over-specifying the statistical models. However, for comparison, we also present results adjusting for these covariates as a secondary analysis. Statistics were calculated using the statistics package STATA, release 7.0 (Statacorp, College Station TX, Stata Corporation, 1997).
RESULTS
The possible influences of baseline covariates were considered. There was no significant association between the risk of composite events and age, sex, or country. The rate of composite events or of MI did not vary significantly between countries. Severe, major, or minor bleeding occurred in 18.7% of patients during follow-up. Genetic samples were taken from patients in the Americas (742), Europe (172) and South Africa (10). There was a significant variation in the risk of bleeding between countries and with increasing age. Comparing those 60 years or over to those under 60, the relative risk (95% confidence interval) of bleeding was 1.44 (1.06-1.97; P ϭ 0.02). Subsequent analyses adjusted for the effects of age, sex, treatment, and country. There was a slight but non-significant deficit of patients on the highest dose of orbofiban in this study (353 on placebo, 353 on 50 mg orbofiban followed by 30 mg orbofiban, 308 on 50 mg orbofiban). This indicates a possible slight bias in the study design, since withdrawal of patients after randomisation but prior to genetic sampling 4 may exclude not only patients whose withdrawal could relate to high drug dose, but also patients whose withdrawal could be influenced by genotype. This latter bias, if any, is harder to quantify.
Overall Genetic Effects
There were 28 myocardial infarctions (MI), and 149 composite endpoints (death, MI, stroke, urgent revascularisation, and recurrent ischemia requiring rehospitalisation). Sixteen of the MI events occurred among the 60% of patients who presented in the study at baseline with MI. One hundred and seventy three patients experienced bleeding, defined as severe, major or minor.
For MI, the finding was that the genetic factors do play a significant role ( 2 ϭ 20.4, 10 df, P = 0.04; Table 2 and Figure  1 ). In contrast, for the composite endpoint, the genes did not confer a significant effect (Table 3 ; P ϭ 0.88). Although certain variants increase bleeding, overall the ten variants have no significant effect (P ϭ 0.13; Table 4 ).
The observation that the overall association of genes with MI is significant assumes that their effects are independent and additive. We defined a pro-thrombotic genotype as car-
The Pharmacogenomics Journal rying one of GPIa T, GPIb Ϫ5C, GPIIb/IIIa PLA2, and a proinflammatory genotype as carrying both IL1RN*2 and IL-6 G. We found no evidence of such an interaction influencing composite endpoint (P ϭ 0.65, the pro-thrombotic RR ϭ 1.2 for those with the pro-inflammatory genotype and RR ϭ 1.0 for those with the non-pro-inflammatory genotype). To look at these risks from a slightly different perspective, if there was a large difference in the two relative risks shown above, it would expected that the ratio of the two risks would differ markedly. However, this is not the case (ratio of RRs ϭ 1.2, CI ϭ 0.6-2.5). This indicates that the test had reasonable power; assuming that the pro-thrombotic genotype confers a relative risk of 1.1 among the non-pro-inflammatory genotype, and a risk of 3.5 among the pro-inflammatory genotype, then there is 80% power to detect a significant interaction (two-sided test). Thus, we did not find evidence that pro-inflammatory and pro-thrombotic polymorphisms interact to cause recurrent events. The advantage of this test is that the factors are genetic, and therefore may be causal; the disadvantage is that their contributions to pro-inflammatory and pro-thrombotic states may be relatively minor. Similar to the findings of the main study, 2 in this genetic sub-study population treatment with orbofiban did not reduce the risk of composite endpoint (P ϭ 0.31) or MI (P ϭ 0.65) but was associated with a significant increase in bleeding (relative risk ϭ 1.68; CI ϭ 1.18, 2.40). We tested whether outcomes were influenced by interactions between the genetic factors and orbofiban. There was a significant interaction between the effects of orbofiban and genotype when looking at bleeding ( 2 ϭ 26.2, 10 df, P ϭ 0.004, Table  4 ) but not when considering MI ( 2 ϭ 9.5, P ϭ 0.49) or composite endpoint ( 2 ϭ 10.9, P ϭ 0.37, Table 3 ). The treatment-group specific association of genotype with bleeding is summarised in Figure 2 .
Individual Gene Effects
The following findings regarding individual gene associations are best interpreted in the light of other studies of Significant genotype-treatment interaction: *P Ͻ 0.05; **P Ͻ 0.001; ***P Ͻ 0.005.
their impact on cardiovascular disease, since in general very large sample sizes 6 are required in order to be conclusive.
Association of genotype with outcomes regardless of treatment
Assessment of the contribution of each genotype revealed no strong predictors of the composite endpoint (Table 3) . Myocardial infarction outcome (Table 2, Figure 1 ) was influenced by the GPIIIa polymorphism (PLA2 carriers RR ϭ 2.3, CI ϭ 1.1-4.8), and was more common among GPIb␣ Ϫ5C carriers (RR ϭ 2.8, CI ϭ 1.3-5.9). Since these two variants have previously been proposed to be pro-thrombotic, these findings are consistent with that model. The influence of the IL-6 pro-inflammatory variant was actually protective of MI (RR ϭ 0.4, CI ϭ 0.2-0.9). Bleeding risk (Table 4) was increased among those with the IL1RN allele *2 (RR ϭ 1.5, CI ϭ 1.1-2.0), and among those carrying the GPIa T allele (RR ϭ 1.5, CI ϭ 1.1-2.2).
Impact of genotype on response to treatment
The effect of PLA2 on the composite endpoint 4 (Table 3 ) was influenced by treatment (test for interaction, P ϭ 0.06). This reflected a higher risk associated with PLA2 in the treated www.nature.com/tpj patients (RR ϭ 1.5, CI ϭ 1.0-2.4) compared to findings among placebo patients (RR ϭ 0.8, CI ϭ 0.4-1.5). The risk associated with the GPIa T allele was confined to the treated patients (RR ϭ 1.8, CI ϭ 1.1-2.9). There were too few MI to permit useful analysis broken down by treatment group. Bleeding responses (Table 4, Figure 2 ) were specifically decreased in the treatment group by the hypothesised prothrombotic variants PLA2 (RR ϭ 0.6, CI ϭ 0.4-1.0) and GPIb␣ Ϫ5C (RR ϭ 0.6, CI ϭ 0.4-1.0). These genetic effects were not only confined to the treatment group, but were somewhat reversed in the placebo (PLA2 RR ϭ 1.4, CI ϭ 0.7-2.6; GPIb␣ Ϫ5C RR ϭ 2.1, CI ϭ 1.1-4.0). A similar pattern was seen for IL-6 (Table 4) . Finally, a very marked protective effect of the MMP9 T allele was seen in the placebo group alone (RR ϭ 0.3, CI ϭ 0.1-0.8).
Individual gene interactions
The sample size is too small for the assessment of individual genotypic interactions, and particularly genotypic interactions influencing treatment response. Exploratory statistical modelling suggested the following possible interactions: (1) those 83 patients on treatment who are PLA2 carriers with the B-fibrinogen GG genotype appear to be at a mark- edly increased risk of MI (10%) compared to the 59 on placebo with this genotypic combination, none of whom experienced MI; (2) vWF-GG genotype only appears to increase risk of MI in the subset of patients who do not carry the −5C variant of the vWF receptor GPIb␣ (OR ϭ 2.8, 95% CI ϭ 1.1-6.9); none of the 34 vWF-GG patients carrying GPIb␣ Ϫ5C experienced MI.
Covariate adjustment
The overall likelihood ratio comparisons for the 10 polymorphisms were carried out allowing for covariates in the model. When the OPUS analyses were adjusted for age, sex, country, race, diabetes, smoking, hypertension requiring drug treatment, cholesterol requiring drug treatment, and family history the following major results were slightly modified: for MI, genetic factors continued to play a significant role ( 2 ϭ 23.7, P ϭ 0.009). Genes were not significantly associated with composite endpoint (P ϭ 0.90); for bleeding, treatment with orbofiban was associated with an increased risk (relative risk ϭ 1.66; CI ϭ 1.17-2.37), the association with genes was of no significance (P ϭ 0.15) and the interaction between the effects of orbofiban and genotype was significant ( 2 ϭ 25.8, P ϭ 0.004). We also analysed the data using the entire dataset of 1014 subjects to include nonCaucasian subjects, and the results were broadly similar.
DISCUSSION
The results of this study demonstrate that genetic polymorphisms are associated with thrombotic and bleed-
The Pharmacogenomics Journal ing outcomes in Caucasian patients with acute coronary syndromes. This is the largest study to date of the impact of genetic factors in this group of patients, comprising 10 genes and over 900 patients. Previous studies had suggested that polymorphisms in two other genes, namely methionine synthase 33 and Factor V Leiden 34 cause subsequent thrombotic events in acute coronary syndrome patients. However, there have been no systematic studies of the association of genetic polymorphism with the recurrence of thrombotic events, so that this study is the largest genetic study of recurrent thrombosis to date. The finding that genetic factors continue to play a role in certain aspects of recurrent thrombotic disease, being associated with myocardial infarction but having little effect on a broader spectrum of ischemia-related outcomes, has implications for our understanding of the role of patients' genetic backgrounds in terms of both the prognosis and possibly the appropriate treatment of their acute coronary syndromes. The variants predisposing to myocardial infarction risk (Figure 1 ) are previously postulated pro-thrombotic variants in the platelet receptor proteins GPIIIa (PLA2) and GPIb␣ (Ϫ5C), but also, less predictably, a variant in the cytokine IL-6 that has been previously associated with reduced inflammation. We sought but did not find any evidence that the pro-thrombotic and pro-inflammatory variants act synergistically to increase disease risk. It should be noted that while we had expectations that the genetic factors would in general increase the risk of coronary disease in the acute coronary syndrome population, since we chose them as risk factors for primary disease, the observations in Figure 1 indicate that some of the departures from expectation are in the opposite direction to that predicted. This heterogeneity in the direction of risk was unexpected. Therefore the conclusion to be drawn is that genetic risk factors for primary disease may influence recurrent disease; however we cannot conclude that such risk factors necessarily increase risk of subsequent MI, only that they modulate the risk in some way.
Bleeding during therapy is an important issue in the management of acute coronary syndromes. We found that the bleeding response to the GPIIb/IIIa antagonist randomised in this trial was strongly modified by genetic variants. These were not only in genes with direct roles in thrombosis and hemostasis such as the platelet receptors GPIa, GPIb␣ and GPIIIa, but also in the MMP-9 gene. Neither were these gene effects necessarily consistent with prior models of the role of the genetic variants: for example, the hypothetically prothrombotic allele GPIa-T actually increased bleeding. It is possible that the role of such variants may depend on the physiological context of the platelet, since the environment of the coronary artery and of the sites of treatment-associated bleeding are likely to be quite different. To widen our understanding of the clinical impact of genetic factors in thrombosis and hemostasis, more studies are needed which, like this one, observe contrasting thrombotic and bleeding cardiovascular phenotypic outcomes within patients. Genetic variation within the drug target GPIIb/IIIa in this study population has an impact on treatment responses, as has been discussed in more detail elsewhere. 4 However, it is clear that bleeding risks in response to treatment are also influenced by genetic factors outside of the drug target. Since these factors are not all associated with platelet receptors, it illustrates that genetic modifiers of treatment responses may occur outside of obvious candidate genes involved in the modulated pathway.
Sample sizes in pharmacogenomic studies are often too small to easily define gene-treatment interactions, particularly when there are multiple candidate genes. [35] [36] [37] [38] The statistical approach used in this study was to avoid excessive reliance on uncorrected tests of individual gene effects, but equally to avoid excessive over-correction for multiple testing. This approach is useful when there is a number of strong candidate alleles, and the purpose is to determine their overall effect on a specific outcome. It answers the broader questions (such as 'Overall, do genetic polymorphisms influence bleeding within an acute coronary syndrome population?') rather than the specific questions (such as 'is GPIb␣ Ϫ5C an important modulator of MI risk?'). Clearly, both kinds of questions are valid and important ones and will be best answered by different study designs. In spite of this approach, the small number of outcomes is a limitation of this study, in particular the relatively small number of MI outcomes. However, our finding that genetic factors may have a role in recurrence of MI and in modulating risk of treatment-associated bleeding should prompt more detailed studies of the subsequent MI risk conferred by GPIIb/IIIa, GPIb␣, and IL-6 in other large studies of acute coronary syndromes. It should also prompt more detailed explorations of the roles of MMP9, IL1RN, GPIb, and GPIIb/IIIa in bleeding. Future studies with greater power could afford to explore not only the primary causal variants, but multiple extended haplotypes at each locus, some of which have the potential to identify risk factors not well identified by analysing individual polymorphisms. 39 While the major clinically relevant polymorphisms at some loci such as fibrinogen 40, 41 appear well represented by the single SNP analysed, for others, such as IL1RN, a haplotypic combination may be more predictive of risk. 19, 42 Genetic factors that influence the risk of a primary coronary event continue to modulate the risk of subsequent MI. Much larger prospective studies will be required to narrow the confidence intervals on the risk conferred by individual genotypes and will need to account for treatment, which can strongly modify conferred risks. This will make metaanalyses across studies difficult except in cases where very similar treatment regimens are applied. In the future, an index of genetic risk may be calculated from a number of genotyping studies of multiple genes, which could identify patients at higher risk who may possibly benefit from more aggressive treatment. 43 In this study, as in other studies, the relative risks conferred by individual genetic variants to ischaemic outcomes are quite small, so that compiling a reliable aggregate genetic risk score would be a considerable technical challenge. Such genotyping assays may permit therapies tailored for particular genotypes, if clear and reprowww.nature.com/tpj ducible genotype-specific treatment effects emerge from multiple studies.
